Biofrontera Inc. (BFRI)
- Previous Close
1.7100 - Open
1.6000 - Bid 1.5600 x 100
- Ask 1.6400 x 100
- Day's Range
1.5601 - 1.7300 - 52 Week Range
0.6100 - 13.4200 - Volume
50,466 - Avg. Volume
782,671 - Market Cap (intraday)
8.092M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-13.0200 - Earnings Date May 12, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
www.biofrontera-us.com83
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BFRI
Performance Overview: BFRI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BFRI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BFRI
Valuation Measures
Market Cap
8.09M
Enterprise Value
12.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.07
Price/Book (mrq)
1.69
Enterprise Value/Revenue
0.35
Enterprise Value/EBITDA
-0.65
Financial Highlights
Profitability and Income Statement
Profit Margin
-59.08%
Return on Assets (ttm)
-33.86%
Return on Equity (ttm)
-140.43%
Revenue (ttm)
34.07M
Net Income Avi to Common (ttm)
-20.13M
Diluted EPS (ttm)
-13.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.42M
Total Debt/Equity (mrq)
112.64%
Levered Free Cash Flow (ttm)
-24.79M